¿ Aethlon Medical Inc., of La Jolla, Calif., said its HIV-Hemopurifier, a modified dialysis cartridge, has demonstrated an ability to rapidly reduce circulating HIV. Preclinical studies have shown the cartridge can remove 90 percent of HIV from human plasma during the equivalent of one overnight treatment.
¿ Cognia Corp., of New York, received a Small Business Innovation Research grant from the National Institute for General Medical Sciences to create a database resource on protein catabolism. The funding will go toward the implementation of a broadly designed system to allow access to relevant primary data and annotated information.
¿ Lorantis Ltd., of London, closed a #11.5 million (US$16.5 million) financing. The second-round financing was led by JPMorgan Partners, of New York, and the funding will go toward drug discovery and development.
¿ Maxim Pharmaceuticals Inc., of San Diego, presented 72-week results from its completed Phase II study of Ceplene (histamine dihydrochloride) in combination with interferon-alpha for the treatment-naove, chronically infected hepatitis C patients. At 72 weeks, the company said, a complete viral response was sustained in 40 percent of evaluable patients in all Ceplene treatment arms combined, and in 44 percent of patients who received the highest dose regimen of Ceplene, formerly called Maxamine.
¿ SCIL Biomedicals GmbH, of Martinsried, Germany, and Biopharm GmbH, of Heidelberg, Germany, entered a partnership to develop a product for the medical regeneration of bone in dental and maxillofacial surgery. The licensing agreement gives SCIL the right to market the jointly owned product worldwide. The product will combine Biopharm¿s patented growth factor MP52 with an appropriate carrier.
¿ Senetek plc, of Napa, Calif., said a European study of 21 patients with erectile dysfunction showed its product, Invicorp, is well tolerated in patients with high blood pressure.